Virtual CROI 2020: Tuberculosis and Coinfections In HIV Infection

Top Antivir Med. 2020 Jun;28(2):455-458.

Abstract

Due to COVID-19, this year marked the first virtual Conference on Retroviruses and Opportunistic Infections (CROI) in the conference's 27-year history. There were important studies presented that provided new insights into the prevention, diagnosis, and treatment of tuberculosis (TB) and other HIV coinfections. Highlights related to TB and HIV coinfections from this year's meeting are reviewed below.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Coinfection / diagnosis
  • Coinfection / drug therapy
  • Coinfection / epidemiology*
  • Communicable Disease Control / organization & administration
  • Congresses as Topic
  • Cryptococcosis / diagnosis
  • Cryptococcosis / drug therapy
  • Cryptococcosis / epidemiology
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • Humans
  • Infant
  • Male
  • Mycoses / diagnosis
  • Mycoses / drug therapy
  • Mycoses / epidemiology
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / epidemiology*
  • Pregnancy
  • Prevalence
  • Primary Prevention / methods
  • Public Health*
  • Risk Assessment
  • Survival Analysis
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • User-Computer Interface
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents

Supplementary concepts

  • talaromycosis